Carlyle Group Amends Jasper Therapeutics Stake, Signals Ownership Update

TL;DR

**Carlyle Group just updated its stake in Jasper Therapeutics, watch for potential market reaction.**

AI Summary

Carlyle Group Inc. filed an amended Schedule 13D/A on February 12, 2024, indicating a change in their beneficial ownership of Jasper Therapeutics, Inc. Voting Common Stock. This amendment, triggered by an event on February 8, 2024, updates previous filings and shows Carlyle's continued significant stake in Jasper Therapeutics. For investors, this matters because Carlyle Group is a major institutional investor, and changes in their holdings can signal their evolving outlook on Jasper Therapeutics' future prospects, potentially influencing market sentiment.

Why It Matters

This filing updates the public on Carlyle Group's current beneficial ownership in Jasper Therapeutics, providing transparency on a major investor's position.

Risk Assessment

Risk Level: low — This is an informational update on an existing significant ownership, not a new acquisition or divestiture, posing low immediate risk.

Analyst Insight

Investors should note Carlyle Group's continued involvement and monitor future filings for any significant changes in their beneficial ownership, as this could indicate a shift in their investment strategy for Jasper Therapeutics.

Key Numbers

• 471871103 — CUSIP Number (identifies Jasper Therapeutics, Inc. Voting Common Stock)
• February 8, 2024 — Date of Event (the specific date that triggered this Schedule 13D/A filing)
• Amendment No. 3 — Filing Amendment Number (indicates this is the third amendment to the original Schedule 13D filing)

Key Players & Entities

• Carlyle Group Inc. (company) — filing person and beneficial owner
• Jasper Therapeutics, Inc. (company) — subject company whose securities are being reported
• Jeffrey Ferguson (person) — person authorized to receive notices for The Carlyle Group
• $0.0001 (dollar_amount) — par value per share of Jasper Therapeutics Voting Common Stock

Forward-Looking Statements

• Carlyle Group will maintain a significant, but potentially adjusted, stake in Jasper Therapeutics. (Carlyle Group Inc.) — medium confidence, target: Next 6-12 months

FAQ

Key Financial Figures

• $0.0001 — ssuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $12.95 — newly-issued Common Stock at a price of $12.95 per share in an underwritten public off

Filing Documents

• d661434dsc13da.htm (SC 13D/A) — 182KB
• d661434dex994.htm (EX-99.4) — 12KB
• 0001193125-24-032344.txt ( ) — 196KB

of the Schedule 13D is hereby amended and supplemented as follows

Item 3 of the Schedule 13D is hereby amended and supplemented as follows: On February 8, 2024, Abingworth Bioventures VII LP purchased 190,000 shares of newly-issued Common Stock at a price of $12.95 per share in an underwritten public offering conducted by the Issuer (the Offering). Abingworth Bioventures VII LP used investment capital to purchase the shares of Common Stock. CUSIP No. 471871103 13D Page 12 of 15 pages Item5. Interest in Securities of the Issuer.

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: (a) (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 14,984,912 shares of Common Stock outstanding as of February 8, 2024, following the completion of the Offering. The amount of Common Stock reported herein reflects a 1-for-10 reverse stock split effected by the Issuer on January 4, 2024. Reporting Person Amount beneficially owned Percent of class Sole power to vote or to direct the vote Shared power to vote or to direct the vote Sole power to dispose or to direct the disposition Shared power to dispose or to direct the disposition The Carlyle Group Inc. 1,066,189 7.1 % 0 1,066,189 0 1,066,189 Carlyle Holdings I GP Inc. 1,066,189 7.1 % 0 1,066,189 0 1,066,189 Carlyle Holdings I GP Sub L.L.C. 1,066,189 7.1 % 0 1,066,189 0 1,066,189 Carlyle Holdings I L.P. 1,066,189 7.1 % 0 1,066,189 0 1,066,189 CG Subsidiary Holdings L.L.C. 1,066,189 7.1 % 0 1,066,189 0 1,066,189 TC Group, L.L.C. 1,066,189 7.1 % 0 1,066,189 0 1,066,189 Carlyle Investment Management L.L.C. 1,066,189 7.1 % 0 1,066,189 0 1,066,189 Carlyle Genesis UK LLC 1,066,189 7.1 % 0 1,066,189 0 1,066,189 Abingworth LLP 1,066,189 7.1 % 0 1,066,189 0 1,066,189 Abingworth Bioventures VII LP 1,066,189 7.1 % 0 1,066,189 0 1,066,189 The shares of Common Stock reported herein are held of record by Abingworth Biovent

of the Schedule 13D is hereby amended and supplemented as follows

Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit Number Description 1 Joint Filing Agreement (previously filed) 4 Power of Attorney. CUSIP No. 471871103 13D Page 14 of 15 pages

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : February 12, 2024 The Carlyle Group Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings I GP Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I GP Sub L.L.C. By: Carlyle Holdings I GP Inc., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I L.P. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CG Subsidiary Holdings L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group, L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CUSIP No. 471871103 13D Page 15 of 15 pages Carlyle Investment Management L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Genesis UK LLC By: Carlyle Investment Management L.L.C., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Abingworth LLP By: /s/ John Heard Name: John Heard Title: Authorized Signatory Abingworth Bioventures VII LP By: /s/ John Heard Name: John Heard Title: Authorized Signatory

View Full Filing

View this SC 13D/A filing on SEC EDGAR